Site-specific patterns of early-stage cancer diagnosis during the COVID-19 pandemic.
Connor J KinslowDavid M DeStephanoAlfred I NeugutKekoa TaparraDavid P HorowitzJames B YuSimon K ChengPublished in: JNCI cancer spectrum (2024)
The COVID-19 pandemic caused widespread disruptions in cancer care. We hypothesized that the greatest disruptions in diagnosis occurred in screen-detected cancers. We identified patients (≥18 years of age) with newly diagnosed cancer from 2019 to 2020 in the US National Cancer Database and calculated the change in proportion of early-stage to late-stage cancers using a weighted linear regression. Disruptions in early-stage diagnosis were greater than in late-stage diagnosis (17% vs 12.5%). Melanoma demonstrated the greatest relative decrease in early-stage vs late-stage diagnosis (22.9% vs 9.2%), whereas the decrease was similar for pancreatic cancer. Compared with breast cancer, cervical, melanoma, prostate, colorectal, and lung cancers showed the greatest disruptions in early-stage diagnosis. Uninsured patients experienced greater disruptions than privately insured patients. Disruptions in cancer diagnosis in 2020 had a larger impact on early-stage disease, particularly screen-detected cancers. Our study supports emerging evidence that primary care visits may play a critical role in early melanoma detection.
Keyphrases
- early stage
- newly diagnosed
- end stage renal disease
- primary care
- ejection fraction
- chronic kidney disease
- sentinel lymph node
- prognostic factors
- squamous cell carcinoma
- peritoneal dialysis
- healthcare
- magnetic resonance imaging
- high throughput
- computed tomography
- childhood cancer
- squamous cell
- single cell
- locally advanced
- drug induced
- adverse drug
- sensitive detection
- label free